Cet anticorp RSV (Palivizumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Fonction
Palivizumab Biosimilar, RSV Monoclonal Antibody
Specificité
The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
Attributs du produit
Recombinant Humanized IgG1 Monoclonal Antibody.
Purification
Protein A affinity column
Pureté
> 95% by SDS-PAGE under reducing conditions and HPLC.
Stérilité
0.2 μm filtered
niveau d'endotoxine
< 1 EU per 1 mg of the protein by the LAL method.
Immunogène
The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Agent conservateur
Without preservative
Conseil sur la manipulation
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.